Creo Medical Group PLC (LON:CREO) Insider Acquires £200,430 in Stock

Creo Medical Group PLC (LON:CREOGet Free Report) insider Kevin Crofton purchased 1,179,000 shares of the stock in a transaction on Friday, December 13th. The shares were purchased at an average cost of GBX 17 ($0.21) per share, with a total value of £200,430 ($251,986.42).

Kevin Crofton also recently made the following trade(s):

  • On Monday, October 21st, Kevin Crofton bought 2,916,666 shares of Creo Medical Group stock. The shares were acquired at an average cost of GBX 24 ($0.30) per share, with a total value of £699,999.84 ($880,060.15).

Creo Medical Group Stock Performance

Shares of CREO stock opened at GBX 16.25 ($0.20) on Thursday. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96. The company has a market cap of £58.79 million, a PE ratio of -270.83 and a beta of 0.86. The company’s fifty day simple moving average is GBX 17.99 and its 200-day simple moving average is GBX 26.09. Creo Medical Group PLC has a 52 week low of GBX 12 ($0.15) and a 52 week high of GBX 50 ($0.63).

About Creo Medical Group

(Get Free Report)

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.

See Also

Receive News & Ratings for Creo Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creo Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.